Rapid test for profiling drug-resistant tuberculosis (DR-TB) as world first
The World Health Organisation announced that a rapid sequencing solution being developed by Oxford Nanopore Technologies meets the globally designated criteria for the clinical diagnosis of drug-resistant tuberculosis (DR-TB).
This is among the first sequencing-based tests to be supported by the WHO in the field of TB – and a significant milestone in the fight against one of the most persistent threats in public health globally.
The rapid test under development by Oxford Nanopore, in collaboration with Quadram Institute is one of three sequencing-based tests for TB endorsed by WHO in a significant step in the global fight against infectious disease.
Read more ➡️https://quadram.ac.uk/the-world-healt...